CA2202472A1 - Ligand pour l-selectine des cellules hematopoietiques (hll) et therapie associee - Google Patents

Ligand pour l-selectine des cellules hematopoietiques (hll) et therapie associee

Info

Publication number
CA2202472A1
CA2202472A1 CA002202472A CA2202472A CA2202472A1 CA 2202472 A1 CA2202472 A1 CA 2202472A1 CA 002202472 A CA002202472 A CA 002202472A CA 2202472 A CA2202472 A CA 2202472A CA 2202472 A1 CA2202472 A1 CA 2202472A1
Authority
CA
Canada
Prior art keywords
cells
glycoprotein
set forth
selectin
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002202472A
Other languages
English (en)
Inventor
Robert Sackstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida St Petersburg
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2202472A1 publication Critical patent/CA2202472A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une glycoprotéine isolée et purifiée et des analogues fonctionnels. Les glycoprotéines sont caractérisées en ce qu'elles sont exprimées sur au moins des cellules hématopoïétiques primitives, et qu'elles constituent un ligand pour L-sélectine. La liaison du ligand sur L-sélectine n'est pas empêchée par des anticorps anti-CD34 ni par l'anticorps monoclonal MECA 79.
CA002202472A 1994-10-11 1995-10-10 Ligand pour l-selectine des cellules hematopoietiques (hll) et therapie associee Abandoned CA2202472A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32140094A 1994-10-11 1994-10-11
US08/321,400 1994-10-11

Publications (1)

Publication Number Publication Date
CA2202472A1 true CA2202472A1 (fr) 1996-04-18

Family

ID=23250468

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002202472A Abandoned CA2202472A1 (fr) 1994-10-11 1995-10-10 Ligand pour l-selectine des cellules hematopoietiques (hll) et therapie associee

Country Status (2)

Country Link
CA (1) CA2202472A1 (fr)
WO (1) WO1996011012A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140903D1 (de) * 2000-10-18 2010-02-04 Brigham & Womens Hospital E-selectin/l-selectin-liganden-polypeptide hämatopoetischer zellen und verfahren zu deren verwendung
EP3336174A1 (fr) 2006-06-02 2018-06-20 Robert Sackstein Compositions et procédés pour modifier des glycans de surface cellulaire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies

Also Published As

Publication number Publication date
WO1996011012A1 (fr) 1996-04-18

Similar Documents

Publication Publication Date Title
Oxley et al. Detection of an L-selectin ligand on a hematopoietic progenitor cell line
Crocker et al. Sialoadhesin binds preferentially to cells of the granulocytic lineage.
Andreesen et al. Human macrophage maturation and heterogeneity: analysis with a newly generated set of monoclonal antibodies to differentiation antigens
Van den Berg et al. Sialoadhesin on macrophages: its identification as a lymphocyte adhesion molecule.
Altevogt et al. The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1.
JP2980928B2 (ja) Ｉｇ‐ｃｄ４融合タンパク質をコードするクローン化された遺伝子及びそれらの用途
Stein et al. Hodgkin and Sternberg‐Reed cells contain antigens specific to late cells of granulopoiesis
US5644033A (en) Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
Charreau et al. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor
US7247718B2 (en) Antibody recognizing a small subset of human hematopoietic cells
CA1171006A (fr) Lignee cellulaire hybride productrice d'un anticorps dirige contre un antigene de lymphocyte t humain, l'anticorps lui-meme et les methodes utilisees
Chin et al. Lymphocyte adhesion to cultured Peyer's patch high endothelial venule cells is mediated by organ-specific homing receptors and can be regulated by cytokines.
Pochon et al. Demonstration of a second ligand for the low affinity receptor for immunoglobulin E (CD23) using recombinant CD23 reconstituted into fluorescent liposomes.
Khar Development and characterization of a rat histiocyte-macrophage tumor line
Haregewoin et al. Cellular expression of a GPI-linked T cell activation protein
AU678179B2 (en) Methods for positive immunoselection of stem cells
Salmi et al. The role of two distinct endothelial molecules, vascular adhesion protein-1 and peripheral lymph node addressin, in the binding of lymphocyte subsets to human lymph nodes
Şeftalioğlu et al. Expression of CD146 adhesion molecules (MUC18 or MCAM) in the thymic microenvironment
US5786160A (en) Natural killer cell-specific antigen and antibodies that identify the same
US5407805A (en) Monoclonal antibody reactive to various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
Bizourane et al. Characterization of membrane sugar-specific receptors in cultured high endothelial cells from mouse peripheral lymph nodes
EP0697880B1 (fr) Inhibition de l'adhesion des leucocytes
CA2202472A1 (fr) Ligand pour l-selectine des cellules hematopoietiques (hll) et therapie associee
CA2190262A1 (fr) Anticorps monoclonal specifique d'un antigene endoglyx-1 de cellules endotheliales vasculaires, l'antigene lui-meme et ses utilisations
US5441871A (en) Monoclonal antibody reactive to human leukemia and lymphoma cells and methods of using same for diagnosis and treatment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead